2023 Current Fiscal Year Report: Advisory Committee on Immunization Practices

Report Run Date: 03/28/2024 02:37:53 PM

1. Department or Agency 2. Fiscal Year

Department of Health and Human

Services

2023

3b. GSA
3. Committee or Subcommittee

Committee No.

14c.

Advisory Committee on Immunization

Practices

768

4. Is this New During 5. Current 6. Expected 7. Expected Fiscal Year? Charter Renewal Date Term Date

No 04/01/2022 04/01/2024

8a. Was Terminated During 8b. Specific Termination Authority 8c. Actual Term Date

No 42 U.S.C. 217a

9. Agency 10b.

Recommendation for Next Req to Terminate?

| Continue of the c

Continue Not Applicable Not Applicable

11. Establishment Authority Authorized by Law

12. Specific 13. 14.

Establishment Effective Commitee Presidential?

Authority Date Type

42 U.S.C. 217a 03/17/1964 Continuing No

15. Description of Committee Scientific Technical Program

Advisory Board

16a. Total

Number of this FiscalYear

Reports

17a. 7 17b. Closed 0 17c. Partially Closed 0 Other Activities 0 17d. Total 7

Open

Meetings and Dates

Purpose Start End

The meeting included discussions on influenza vaccines, pneumococcal vaccine, meningococcal vaccines, respiratory syncytial virus vaccine, rotavirus vaccine, dengue vaccines, adult immunization schedule, child/adolescent immunization schedule, COVID-19 vaccines and Chikungunya vaccine. Recommendation votes on pneumococcal, adult immunization schedule, child/adolescent immunization schedule and COVID -19 vaccines are scheduled. A Vaccines for Children (VFC) vote on COVID-19 vaccine is scheduled.

10/19/2022 - 10/20/2022

The meeting included discussions on mpox vaccines, influenza vaccines, pneumococcal vaccine, varicella vaccines, meningococcal vaccines, Polio vaccine, respiratory syncytial virus vaccine pediatric/maternal, respiratory 02/22/2023 - 02/24/2023

syncytial virus vaccine adult, dengue vaccines, Chikungunya vaccine, and COVID-19 vaccines. A recommendation vote on mpox vaccine is scheduled.

The meeting included discussions on COVID-19 vaccines. No recommendation votes were scheduled.

04/19/2023 - 04/19/2023

The meeting included discussions on mpox vaccines, influenza vaccines, pneumococcal vaccines, meningococcal vaccines, polio vaccine, respiratory syncytial virus vaccine pediatric/maternal, respiratory syncytial virus vaccine in adults, dengue vaccines, chikungunya vaccine, and COVID-19

06/21/2023 - 06/23/2023

vaccines. Recommendation votes on influenza vaccines, pneumococcal vaccines, polio vaccines, and respiratory syncytial virus vaccine in adults are scheduled. Vaccines for Children votes on influenza and pneumococcal vaccines are scheduled.

The meeting included discussion of nirsevamab for prevention of respiratory syncytial virus (RSV). A recommendation vote and a Vaccines for Children vote are scheduled.

08/03/2023 - 08/03/2023

The meeting included discussion of

COVID-19 vaccines. Recommendation votes 09/12/2023 - 09/12/2023 for COVID-19 vaccines are scheduled.

The meeting included discussions of maternal respiratory syncytial virus (RSV) vaccine and child/adolescent immunization schedules and adult immunization schedule. A recommendation vote for maternal RSV vaccine is scheduled. A Vaccines for Children vote is scheduled for maternal RSV

09/22/2023 - 09/22/2023

Number of Committee Meetings Listed: 7

Current FY Next FY

18a(1). Personnel		
Pmts to	\$37,500.00	\$42,500.00
Non-Federal	ψ57,300.00	ψ+2,000.00
Members		
18a(2). Personnel		
Pmts to Federal	\$0.00	\$0.00
Members		
18a(3). Personnel		
Pmts to Federal	\$2,305,960.00\$	\$1,760,637.00
Staff		
18a(4). Personnel		
Pmts to	# 0.00	# 0.00
Non-Member	\$0.00	\$0.00
Consultants		
18b(1). Travel and		
Per Diem to	# 40.400.00	# 50.050.00
Non-Federal	\$49,132.00	\$50,853.00
Members		
18b(2). Travel and		
Per Diem to	\$0.00	\$0.00
Federal Members		
18b(3). Travel and		
Per Diem to	\$3,453.00	\$2,905.00
Federal Staff		
18b(4). Travel and		
Per Diem to	40.00	# 0.00
Non-member	\$0.00	\$0.00
Consultants		
18c.		
Other(rents,user	***	# 040 004 00
charges, graphics,	\$310,493.00	\$313,664.00
printing, mail, etc.)		
18d. Total	\$2,706,538.00\$	\$2,170,559.00
19. Federal Staff		•
Support Years	13.30	9.40
(FTE)		
` '		

20a. How does the Committee accomplish its purpose?

The Advisory Committee on Immunization Practices (ACIP) formulates and updates recommendations on the most appropriate use of vaccines and related agents for the civilian population in the United States, and disseminates this information to assist States and their political subdivisions in the prevention and control of vaccine-preventable diseases. Section 13631 of the Omnibus Budget Reconciliation Act of 1993 (OBRA) established a "Vaccines for Children" (VFC) program. This legislation mandated ACIP to establish a list of vaccines for routine administration to children and adolescents through 18 years of age, along with schedules on the appropriate dosing interval, dose, and contraindications applicable to the pediatric vaccines. This list is used by the Secretary of HHS for the purpose of purchase, delivery, and administration of pediatric vaccines.

20b. How does the Committee balance its membership?

During FY23, committee members included experts in the area of use of vaccines and immunologic agents, preventive medicine, epidemiology, infectious diseases, internal medicine, pediatrics, preventive medicine, public health, immunology, and a consumer representative. The racial, ethnic and geographic composition reflects that of the US population; 64% of members are female and 36% of members represent members of racial/ethnic minority groups. Applications are actively solicited from professional organizations representing minority populations.

20c. How frequent and relevant are the Committee Meetings?

The committee met 7 times during FY23. This

committee makes vaccine recommendations for FDA licensed vaccines for use in children, adolescents and adults in the United States, regularly evaluates immunization practices in the United States and recommends needed changes, based on evaluation of the risks and benefits of available vaccines and related agents and delivery mechanisms necessary to promote activities in the public and private health sectors. Periodic assessment and revisions are required to the ACIP generated childhood and adult immunization schedules as more data about existing vaccines become available, and as new vaccines become licensed. ACIP continues to address the responsibilities mandated under OBRA.

20d. Why can't the advice or information this committee provides be obtained elsewhere?

The committee serves a vitally important role for the U.S. in regularly evaluating the use of vaccines and related agents available for prevention and control of vaccine-preventable diseases in this country to optimize the public health benefits. Its recommendations are based on evaluation of the risks and benefits of vaccines and related agents, and their advice is evidence-based. The committee's responsibilities meet a continuous need for regular review and updating of policies affecting all aspects of evolving immunization practices. There are no existing suitable alternative processes to meet this need.

20e. Why is it necessary to close and/or partially closed committee meetings?

21. Remarks

No reports required for this committee.

Government facilities are used for meetings, eliminating the need for meeting space rental. Members who retired after FY22 CD-1937348 C.Baker, CD-1937344 M. Hogue.

Designated Federal Officer

Melinda Wharton Executive Secretary

Melinda Wharton Executive Secretary				
Committee Members	Start	End	Occupation	Member Designation
Anderson, Evan	08/01/2022	12/31/2022	Emory University	Representative Member
Arthur, Phyllis	02/01/2015	06/30/2024	Senior Director, Vaccines, Immunotherapeutics and Diagnostics Policy	Representative Member
Bahta, Lynn	07/01/2019	12/31/2023	MN Dept of Health	Special Government Employee (SGE) Member
Baker, Carol	01/30/2019	10/01/2022	Baylor College of Medicine	Representative Member
Barnett, Elizabeth	01/01/2020	06/30/2024	Boston University School of Medicine	Representative Member
Beigel, John	10/01/2018	06/30/2027	Associate Director for Clinical Research	Ex Officio Member
Bell, Beth	07/01/2019	12/31/2023	University of WA	Special Government Employee (SGE) Member
Brooks, Oliver	07/26/2021	06/30/2025	Watts HealthCare Corporation	Special Government Employee (SGE) Member
Chai, Thevy	03/01/2020	06/30/2024	University of N. Carolina	Representative Member
Chen, Wilbur	12/23/2020	06/30/2024	University of Maryland School of Medicine	Special Government Employee (SGE) Member
Cineas, Sybil	07/28/2021	06/30/2025	The Warren Alpert Medical School of Brown University	Special Government Employee (SGE) Member
Clark, Matthew	10/01/2022	10/05/2024	Chair, IHS National Pharmacy & Therapeutics Committee	Ex Officio Member
Coyle, Rebecca	02/01/2018	06/30/2024	Executive Director	Representative Member

Daley, Matthew	01/04/2021	06/30/2024	Kaiser Permanente Colorado	Special Government Employee (SGE) Member
Deeks, Shelley	06/09/2021	06/30/2024	Deputy Chief Medical Officer of Health, Department of Health and Wellness, Nova Scotia	Representative Member
Drees, Marci	06/01/2020	02/24/2023	Thomas Jefferson University	Representative Member
Duchin, Jeffrey	01/01/2020	06/30/2024	University of WA	Representative Member
Eckert, Linda	10/01/2018	06/30/2027	Professor, Department of Obstetrics & Gynecology, University of Washington	Representative Member
Fink, Doran	10/01/2018	12/01/2022	Director	Ex Officio Member
Fryhofer, Sandra	07/01/2015	06/30/2024	Emory University School of Medicine	Representative Member
Gluckman, Robert	03/01/2020	06/30/2024	Providence Health Plans	Representative Member
Goldman, Jason	10/01/2018	06/30/2027	Affiliate Assistant Professor of Clinical Biomedical Science, Florida Atlantic	-
Goode, Jean-Venable "Kelly"	05/02/2022	10/01/2027	Professor and Director, PGY1 Community-Based Pharmacy Residency Program School of Pharmacy, Virginia Commonwealth University Director Health	Representative Member
Grimes, Reed	07/01/2022	06/30/2027	Resources and Services Administration (HRSA)	Ex Officio Member
Grogg, Stanley	07/01/2011	06/30/2024	Oklahoma State University-Center for Health Sciences	Representative Member
Grubb, Jessica	11/18/2022	10/01/2026	Medical Director, Infectious Diseases, Elevance Health Companies/Carelon	Representative Member
Hahn, Christine	07/01/2011	06/30/2024	Idaho Department of Health and Welfare	Representative Member

Hance, Mary Beth	09/01/2011	06/30/2027	Senior Policy Advisor, Division of Quality, Evaluations and Health Outcomes	Ex Officio Member
Hayes, Carol	01/01/2015	06/30/2024	GA State School of Nursing	Representative Member
Hogue, Michael	07/01/2022	11/01/2024	Loma Linda University	Representative Member
Howell, Molly	11/12/2020	06/30/2024	North Dakota Department of Health	Representative Member
James, Loehr	07/26/2021	06/30/2025	Cayuga Family Medicine	Special Government Employee (SGE) Member
Juthani, Manisha	10/03/2022	10/01/2027	Commissioner, Connecticut Department of Public Health	Representative Member
Kim, David	12/01/2020	06/23/2023	Director, OIDP	Ex Officio Member
Kimberlin, David	10/10/2010	06/30/2024	UAB Pediatrics	Representative Member
Kotton, Camille	12/23/2020	06/30/2024	Harvard Medical School	Special Government Employee (SGE) Member
Lee, Grace	12/23/2020	12/31/2023	Professor of Pediatrics, Stanford University School of Medicine	
Leger, Marie-Michele	11/01/2020	06/30/2024	AAPA Clinical Director	Representative Member
Long, Sarah	12/24/2020	06/30/2024	St. Christopher's Hospital for Children	Special Government Employee (SGE) Member
Marks, Peter	12/01/2022	06/30/2027	Director of the Center for Biologics Evaluation and Research (CBER)	Ex Officio Member
Marshall, Valerie	06/26/2023	06/30/2027	Deputy Director Office of Infectious Disease and HIV/AIDS Policy (OIDP)	Ex Officio Member
McMullen, Sharon	03/01/2020	06/30/2024	Cornell Health	Representative Member
McNally, Veronica	10/31/2018	12/31/2023	Fanny Strong Foundation	Special Government Employee (SGE) Member
Mehrotra, Preeti	02/24/2023	10/01/2027	Senior Medical Director, Harvard Medical School	Representative Member

Middleman, Amy	07/01/2011	06/30/2024	University of Oklahoma Health Sciences Center	Representative Member
O'Leary, Sean	10/01/2015	06/30/2024	Children's Hospital Colorado	Representative Member
Paulsen, Grant	01/17/2023	06/30/2027	Associate Professor of Pediatrics Pediatric Infectious Diseases, Cincinnati Children's Hospital Medical Center	Representative
Poehling, Katherine	07/01/2019	12/31/2023	Wake Forest School of Medicine	Special Government Employee (SGE) Member
Rittle, Charles	09/01/2014	06/30/2024	American Medical Association (AMA)	Representative Member
Robertson, Corey	09/01/2018	06/30/2024	Senior Director, US Medical, Sanofi Pasteur	Representative Member
Rockwell, Pamela	02/01/2018	06/30/2027	University of Michigan Medical School	Representative Member
Sanchez, Pablo	07/01/2019	12/31/2023	Nationwide Children's Hospital	Special Government Employee (SGE) Member
Schaffner, William	07/01/2011	06/30/2024	Vanderbilt University School of Medicine	Representative Member
Schmader, Kenneth	10/10/2010	06/30/2024	Duke University and Durham VA Medical Centers	Representative Member
Shah, Nirav	09/26/2022	06/30/2023	Maine CDC	Special Government Employee (SGE) Member
Stinchfield, Patricia	07/01/2011	06/30/2024	Children's Hospitals and Clinics of Minnesota	Representative Member
Talbot, Helen	10/29/2018	12/31/2023	Vanderbilt University	Special Government Employee (SGE) Member
Whitley-Williams, Patricia	07/01/2011	06/30/2024	Robert Wood Johnson Medical School	Representative Member
Zahn, Matthew	11/01/2011	06/30/2024	Orange County Health Care Agency	Representative Member
Zimmerman, Richard	09/20/2021	06/30/2024	Professor, Pittsburg SoM	Representative Member

Number of Committee Members Listed: 60

Narrative Description

The ACIP provides advice to the Secretary, HHS; the Assistant Secretary for Health; and the Director, CDC on the most effective means to prevent vaccine-preventable diseases. The committee accomplishes this through written recommendations for the routine administration of vaccines to the childhood and adult populations regarding the appropriate dosing interval, dose, and contraindications to immunization.

What are the most significant program outcomes associated with this committee?

	Checked if
	Applies
Improvements to health or safety	~
Trust in government	✓
Major policy changes	✓
Advance in scientific research	
Effective grant making	
Improved service delivery	
Increased customer satisfaction	
Implementation of laws or regulatory	
requirements	
Other	
Outcome Comments	
NA	
What are the cost savings associated with t	his committee?
	Checked if Applies
None	√
Unable to Determine	
Under \$100,000	
\$100,000 - \$500,000	
\$500,001 - \$1,000,000	
\$1,000,001 - \$5,000,000	
\$5,000,001 - \$10,000,000	
Over \$10,000,000	
Cost Savings Other	

Cost Savings Comments

Not applicable.

What is the approximate <u>Number</u> of recommendations produced by this committee for the life of the committee?

286

Number of Recommendations Comments

The ACIP was chartered under the Federal Advisory Committee Act (PL 92-463) in 1964. All recommendations affect the civilian population in the U.S. and support the Vaccines for Children Program.

What is the approximate <u>Percentage</u> of these recommendations that have been or will be <u>Fully</u> implemented by the agency?

100%

% of Recommendations Fully Implemented Comments

All recommendations have been accepted and implemented by State and local Health Departments and are endorsed by professional organizations such as AAP, AAFP, ACP, ACOG, and ACNM.

What is the approximate <u>Percentage</u> of these recommendations that have been or will be <u>Partially</u> implemented by the agency?

0%

% of Recommendations	Partially Implemented	Comments
N/A		

Does the agency provide the committee with feedback regarding actions taken to implement recommendations or advice offered?

Yes 🗸	No 🗔	Not Applicable

Agency Feedback Comments

The agency provides feedback to the public through its public webcast of the meeting, summaries of recommendations on the ACIP website, public media statements and social media posts, and published statements in the Morbidity and Mortality Weekly Report, which is available online.

What other actions has the agency taken as a result of the committee's advice or recommendation? Checked if Applies **Reorganized Priorities** Reallocated resources Issued new regulation Proposed legislation Approved grants or other payments Other **Action Comments** N/A Is the Committee engaged in the review of applications for grants? No **Grant Review Comments** ACIP is not a grant review committee. How is access provided to the information for the Committee's documentation? Checked if Applies Contact DFO Online Agency Web Site Online Committee Web Site Online GSA FACA Web Site

Access Comments

Publications

N/A

Other